Subscribe
shutterstock_1644424099_angellodeco
angellodeco / Shutterstock.com
30 June 2020Americas

Labrador drops BioFire suit after COVID-19 revelation

Labrador Diagnostics has dropped its controversial patent complaint against COVID-19 test developer  BioMerieux.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fortress offers licences after COVID-19 testing patent backlash
19 March 2020   Labrador Diagnostics, a subsidiary of Fortress Investment Group, has offered royalty-free licences to third parties for its patent-protected diagnostics technology, just days after suing US-based health startup BioFire, which is attempting to develop COVID-19 testing kits.
Medtech
COVID-19: governments look to shield companies from IP enforcement
23 April 2020   The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Fortress offers licences after COVID-19 testing patent backlash
19 March 2020   Labrador Diagnostics, a subsidiary of Fortress Investment Group, has offered royalty-free licences to third parties for its patent-protected diagnostics technology, just days after suing US-based health startup BioFire, which is attempting to develop COVID-19 testing kits.
Medtech
COVID-19: governments look to shield companies from IP enforcement
23 April 2020   The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.

More on this story

Americas
Fortress offers licences after COVID-19 testing patent backlash
19 March 2020   Labrador Diagnostics, a subsidiary of Fortress Investment Group, has offered royalty-free licences to third parties for its patent-protected diagnostics technology, just days after suing US-based health startup BioFire, which is attempting to develop COVID-19 testing kits.
Medtech
COVID-19: governments look to shield companies from IP enforcement
23 April 2020   The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?